Menu
Back to Journals » Infection and Drug Resistance » Volume 6
The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae
Authors Miossec C, Claudon M, Levasseur P, Black MT
Received 1 September 2013
Accepted for publication 7 October 2013
Published 3 December 2013 Volume 2013:6 Pages 235—240
DOI https://doi.org/10.2147/IDR.S53874
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Christine Miossec, Monique Claudon, Premavathy Levasseur, Michael T Black
Novexel, Romainville, France
Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae was investigated by ampC messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as ampC inducers, whereas avibactam was found to exert no effect on ampC expression. Thus, avibactam is unlikely to diminish the activity of any partner β-lactam antibiotic against AmpC-producing organisms.
Keywords: β-lactamase, ampC, induction, NXL104, avibactam
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.